Schoenfeld and colleagues identified two clinically distinct classes of SMARCA4 alterations in metastatic NSCLC, both significantly enriched in tumors co-mutated with KRAS, STK11, and KEAP1, compared to SMARCA4 wild-type (p < 0.001), [28]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.